Search
Research
Bilateral murine tumor models for characterizing the response to immune checkpoint blockadeThis protocol describes bilateral murine tumor models that display a symmetrical yet dichotomous response to immune checkpoint blockade
Research
Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemiaOur study provides evidence that OT-82 is a promising new therapeutic strategy for a broad spectrum of high-risk pediatric acute lymphoblastic leukemia
News & Events
Big run ends, race for cure continuesOur local legend, brain cancer researcher Jacob Byrne, has crossed the finish line of his final marathon, completing his Big Run for Little Brains - 30 marathons in 30 days, covering 1266km across Perth’s local government areas.
News & Events
Delivering smart drugs into cellsThe Drug Discovery Unit has been finding ways for smart drugs to penetrate deep into cells and attacking their disease targets while causing fewer side effects
News & Events
New test proves effective in more cancersAvantogen Limited (ACU:ASX) today announced that cancer researchers at Perth's The Kids for Child Health Research (TICHR) and Avantogen Limited
News & Events
National study to unravel triggers for childhood leukaemiaA national study is investigating diet, chemical exposure and genetic factors in a new bid to unravel the causes of childhood leukaemia.
Research
The Australian and New Zealand Children's Haematology/Oncology Group Biobanking NetworkThe ANZCHOG-BN is a new biobank network in Australasia that was developed to improve and streamline access to high-quality pediatric and AYA cancer biospecimens
Research
Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemiaWe found two known risk factors in a large cohort of children treated for ALL and identified other factors associated with venous thromboembolism
Research
Acquired resistance during adoptive cell therapy by transcriptional silencing of immunogenic antigensThese findings suggest that tumor cells employ multiple epigenetic and genetic mechanisms to evade immune control
Research
Romidepsin enhances the efficacy of cytarabine in vivo, revealing HDAC inhibition as a therapeutic strategy for KMT2A-rearranged acute lymphoblastic leukemiaIn this study, we investigate the in vivo synergy between romidepsin and cytarabine